NextCell Pharma Investor Relations Material
Latest events
Study Result
NextCell Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from NextCell Pharma
Access all reports
NextCell Pharma AB is a Swedish biopharmaceutical company specializing in the development of novel stromal cell therapies, primarily focusing on treatments for autoimmune and inflammatory diseases. Its flagship product, ProTrans, targets type 1 diabetes. The company also operates Cellaviva, the largest private stem cell bank in Scandinavia, which stores and processes stem cells from umbilical cords. NextCell Pharma integrates both therapeutic development and biobanking services within its operations. The company is headquartered in Huddinge, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
NXTCL
Country
🇸🇪 Sweden